Results 41 to 49 of about 50 (49)
Some of the next articles are maybe not open access.
Compelling evidence for unconditional shift to dolutegravir
The Lancet HIV, 2022Kim, Steegen, Lucia, Hans
openaire +2 more sources
Dolutegravir drug-resistance monitoring in Africa
The Lancet HIV, 2021Seth C Inzaule +2 more
openaire +3 more sources
High-level Dolutegravir Resistance Selection on Dolutegravir/Lamivudine
Clinical Infectious DiseasesLlibre, JM, Jou, A, Puig, T
openaire +3 more sources
Insights in Dolutegravir-Resistance Pathways
Clinical Infectious DiseasesThibault Mesplede, Pierre Gantner
openaire +2 more sources
Dolutegravir—a promising antiretroviral in development
The Lancet Infectious Diseases, 2012openaire +3 more sources
Colitis apoptótica por dolutegravir
Gastroenterología y Hepatología, 2020Iago Rodríguez-Lago +3 more
openaire +2 more sources
Opportunities and limits for dolutegravir in late pregnancy
The Lancet HIV, 2020openaire +2 more sources